News | Radiation Therapy | April 22, 2019

Medicaid Reimbursement for Radiation Therapy Varies Widely by State

Substantial differences in Medicaid compensation for standard-of-care breast cancer treatment indicate larger trend in cancer care

Comparison of state Medicaid fees for radiation oncology services for breast cancer and nonradiation oncology services per the Kaiser Family Foundation Index

Fig. 1: Comparison of state Medicaid fees for radiation oncology services for breast cancer and nonradiation oncology services per the Kaiser Family Foundation Index. (Agarwal et al, Red Journal, 2019) Credit: Elsevier

State Medicaid fees for a course of radiation therapy for breast cancer

Fig. 2: State Medicaid fees for a course of radiation therapy for breast cancer (excluding deep inspiratory breath hold). The Kaiser Family Foundation Fee Index for each state is plotted on the X axis and the total cost of care for a course of radiation therapy (fees for image guidance for respiratory tracking excluded) is plotted on the Y axis. The correlation coefficient of the Kaiser Family Foundation Index to the calculated entire episode of care fees for each state was 0.55. (Agarwal et al, Red Journal, 2019) Credit: Elsevier

April 22, 2019 — A new study finds wide state-by-state variations in Medicaid reimbursements to physicians who treat cancer patients with radiation therapies. These differences could compound existing disparities in access to healthcare in rural communities, which tend to have higher Medicaid coverage rates than metropolitan areas. The study is available for free access through April 24 in the International Journal of Radiation Oncology • Biology • Physics (Red Journal), the flagship scientific journal of the American Society for Radiation Oncology (ASTRO).1

“Roughly 66 million low-income Americans are enrolled in Medicaid, and we know from previous studies that these patients face disproportionate difficulty and delays getting the care they need,” said Ankit Agarwal, M.D., MBA, first author of the study and a radiation oncology resident physician at the University of North Carolina at Chapel Hill. “With cancer care, timely treatment matters, and states that under-compensate for radiation therapy likely undermine patients’ health outcomes.”

For the analysis, researchers examined 2017 Medicaid fee schedules from 48 states and the District of Columbia2. Key findings included:

  • Fivefold difference in reimbursement rates: The average reimbursement for standard-of-care radiation therapy to treat breast cancer3 ranged from a low of $2,945 in New Hampshire, to a high of $15,218 in Delaware, with an overall average of $7,233 for an entire episode of care.
  • Radiation oncology disproportionately affected: The variation in radiation therapy payments outpaces the differences seen with other Medicaid reimbursements. Analysis of the Kaiser Family Foundation Medicaid-to-Medicare fee index for general medical services found that reimbursement ratios ranged from a low of 0.38 in Rhode Island to a high of 1.26 in Alaska — a threefold difference. By comparison, the authors’ index of radiation oncology payments showed a fivefold difference.

“Clinics that provide radiation therapy also have expensive fixed costs to purchase and maintain the equipment used for treatments. Inadequate and disproportionate Medicaid reimbursement rates — which already fall below comparable Medicare rates — can negatively impact the viability of facilities, especially in rural and private practice settings. Any reduction in the number of facilities in these areas can limit or remove patient access to these life-saving medical services,” explained Agarwal.

“Greater stability and fairness in Medicaid compensation would help stabilize access for Medicaid patients and make it more financially feasible for the physicians who care for them, especially in rural communities and those with fewer physicians overall. If left unaddressed, however, the disparity could aggravate the growing maldistribution of radiation oncologists in rural and urban communities — and place low-income patients in rural communities at even greater threat.”

For more information: www.redjournal.org

References

1. Agarwal A., Peterson J., Hoyle L., et al. Variations in Medicaid Payment Rates for Radiation Oncology. International Journal of Radiation Oncology • Biology • Physics, published online March 31, 2019. DOI: org/10.1016/j.ijrobp.2019.02.031

2. Findings are based on Medicaid fee schedules from the fourth quarter of 2017, obtained from the state Medicaid websites or departments. Two states were not included in the analysis: Tennessee does not follow a Medicaid fee-for-service model, and Illinois’ fee schedule was incomplete.

3. The reference case was a patient who received hypofractionated radiation therapy for breast cancer, using the deep inspiration breast hold (DIBH) technique and a radiation boost to the tumor bed. This clinical scenario is one of the most common in radiation oncology; Agarwal also noted that reimbursement for this treatment scenario is generally reflective of how radiation oncology is reimbursed for other commonly-treated sites.

Related Content

A new framework from an international team of experts aims to help protect patients and providers, and conserve protective equipment for frontline healthcare workers #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Prostate Cancer | March 30, 2020
March 30, 2020 — In the wake of the COVID-19 pan
Women are more likely to be cured of cancer by radiotherapy but the side effects are worse.

Women are more likely to be cured of cancer by radiotherapy but the side effects are worse. Image by Mark Kostich

News | Radiation Therapy | March 30, 2020
March 30, 2020 — Women undergoing radiotherapy for
Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | March 19, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
A University of Colorado Cancer Center study published in the Journal of the National Cancer Institute shows an important predictor of PET-CT use

Rustain Morgan, M.D., and colleagues show racial/ethnic disparities in use of important imaging during lung cancer diagnosis. Photo courtesy of University of Colorado Cancer Center

News | PET-CT | March 12, 2020
March 12, 2020 — The use of PET-CT
SoftVue image stacks of sound speed, as shown for cases ranging across the four Breast Imaging Reporting and Data System (BI-RADS) breast density categories

Example: SoftVue image stacks of sound speed, as shown for cases ranging across the four Breast Imaging Reporting and Data System (BI-RADS) breast density categories ((a), fatty; (b), scattered; (c), heterogeneously dense; (d), extremely dense). Note the quantitative scale indicating that absolute measurements are obtained. Image courtesy of MDPI

News | Breast Imaging | March 10, 2020
March 10, 2020 — ...
Schematic depiction of the automated process for assessing fat, muscle, liver, aortic calcification, and bone from original abdominal CT scan data

Figure 1: Depiction of the fully automated CT biomarkers tools used in this study. (A) Schematic depiction of the automated process for assessing fat, muscle, liver, aortic calcification, and bone from original abdominal CT scan data. (B) Case example in an asymptomatic 52-year-old man undergoing CT for colorectal cancer screening. At the time of CT screening, he had a body-mass index of 27·3 and Framingham risk score of 5% (low risk). However, several CT-based metabolic markers were indicative of underlying disease. Multivariate Cox model prediction based on these three CT-based results put the risk of cardiovascular event at 19% within 2 years, at 40% within 5 years, and at 67% within 10 years, and the risk of death at 4% within 2 years, 11% within 5 years, and 27% within 10 years. At longitudinal clinical follow-up, the patient suffered an acute myocardial infarction 3 years after this initial CT and died 12 years after CT at the age of 64 years. (C) Contrast-enhanced CT performed 7 months before death for minor trauma was interpreted as negative but does show significant progression of vascular calcification, visceral fat, and hepatic steatosis. HU=Hounsfield units.

News | Computed Tomography (CT) | March 06, 2020
March 6, 2020 — Researchers at the National Institutes of Health a
M. Minhaj Siddiqui, M.D., associate professor of surgery at the University of Maryland School of Medicine, discusses benefits of MRI-targeted biopsy to more precisely diagnose aggressive prostate cancers

M. Minhaj Siddiqui, M.D., associate professor of surgery at the University of Maryland School of Medicine, discusses benefits of MRI-targeted biopsy to more precisely diagnose aggressive prostate cancers. (c) University of Maryland Greenebaum Comprehensive Cancer Center

News | Prostate Cancer | March 05, 2020
March 5, 2020 — Using a combination of...
Accuray Incorporated announced that Mercy Hospital St. Louis continues to demonstrate its commitment to improving patient outcomes with the installation of the first CyberKnife M6 System in Missouri at their state-of-the-art David C. Pratt Cancer Center
News | Stereotactic Body Radiation Therapy (SBRT) | February 27, 2020
February 27, 2020 — Accuray Incorporated announced that Mercy
Christopher Comstock, M.D., ECOG-ACRIN Cancer Research Group study published in JAMA builds evidence for use of abbreviated MRI in women with dense breasts

Christopher Comstock, M.D., (Memorial Sloan Kettering Cancer Center) is the lead author of a paper in JAMA that reports that abbreviated breast MRI detected significantly more (almost 2 and a half times as many) breast cancers than digital breast tomosynthesis (3-D mammography) in average-risk women with dense breasts. Photo courtesy of Memorial Sloan Kettering Cancer Center

News | Breast Imaging | February 26, 2020
February 26, 2020 — According to a study
An example of the MRI scans showing long-term and short-term survival indications. #MRI

An example of the MRI scans showing long-term and short-term survival indications. Image courtesy of Case Western Reserve University

News | Magnetic Resonance Imaging (MRI) | February 21, 2020
February 21, 2020 — ...